Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You will have 3 glasses of wine and blurt to somebody. I am sure if this goes to $2 or higher I will do the same.
That is because once you get rich you will hear from all your relatives.
None of the adjacent claims are active.
Filing out
I can't wait to see the soil assay reports. There are no active claims close to Miller's Rock Creek 80 acre claims. Every claim close by was abandoned 50 years ago. The town of Atlantic City, the closest mining town, is basically a ghost town with a shop for hikers. The closest lithium is 30 miles away.
If Miller finds anything substantial then I will be more than impressed with his effort here.
If nothing happens here, I honestly won't be that disappointed. This is a big puzzle put together by Ecomike and if it hits then it will be a very fun story to tell about a big profit.
I have some fraud software that I use to find people and their personal cell phones and personal emails. I have attempted to contact all of the people involved in this company and nobody is saying a word. I know for a fact that the emails are correct. Kubin also is a friend of my uncle so I know that he recognized my name. Nevertheless, nobody is saying a damn word. I think if the shell were dead it would have been very easy for somebody answer my email with a one word response also.
This is definitely fun to watch. I am sitting patiently waiting to find out what will happen. I think there is something here. If there were anything negative out there that I could find you can bet that I would disclose it as well.
The Rock Springs uplift is nowhere near Mark Miller’s claims. The uplift with lithium runs 50 miles due north of rock springs Wyoming. Millers claims are due east of Atlantic City Wyoming. Millers claims are more than 30 miles away from the outer boundary of the Rock Springs uplift.
Good luck with that. I think you will find Nick to be a nice intelligent man.
Why do you say Lithium when there is no lithium mining in Miller's claim area near Beaver Creek East of Atlantic City in Sec 9?
You did mean Rock Springs and it is a good 30 miles away from what I can see. The idea that the formation is close to Miller's claim is just not true. Miller claim in on land that has no active claims nearby and so was very inexpensive to procure.
I look forward to seeing the soil assay results.
I think you mean Rock Springs uplift which is fairly far south of Atlantic City.
You have 3 published addresses and they are all hotels.
The simplest answer is most probably correct- he is using hotel addresses to keep people away from his actual office. I am sure that spoofing an address is frowned upon but this can be easily corrected at the right time.
"I have done conversions" and "I am not dumping" and no form 13 tells you that he has converted fewer than 20 million of his shares.
That would be incredible Berkshire, because all of the claims in the area are dead and abandoned after having first been prospected in the 1860s and abandoned for the most part 50 years ago.
https://thediggings.com/usa/wyoming/map
Add to that- the address for the company at otcmarkets is a Residence Inn.
8400 Old Courthouse Road Vienna, VA 22182
Hovis appears to be using hotel addresses for all of these corporate documents.
That is not true. You should ask RB Capital about that.
.66 canadian is the same as .52 usd.
The shell risk designation should drop off now as well.
The minute the ADVA-27a arrived the trials started. The QC work is in fact part of the trials.
From Bioworld today-
Sunshine Biopharma Inc., of Montreal, said it has received about $2.05 million from its committed minimum financing of $2 million with RB Capital Partners Inc. The financing is in the form of fixed-price convertible debt, which now stands at a weighted average conversion price of 43 cents per share. Proceeds are funding ongoing development of the company’s discovery-stage coronavirus compounds and development of Adva-27a, its preclinical DNA topoisomerase II alpha inhibitor targeting pancreatic cancer. In February 2021, Sunshine initiated a transgenic mice study for its anti-coronavirus compounds in collaboration with the University of Georgia to determine whether the protease inhibitors protect hACE2-transgenic mice from progression to disease and death following infection with SARS-CoV-2, potentially leading to IND submissions to the FDA and Health Canada.
https://www.bioworld.com/articles/505313-financings-for-march-30-2021
there is an independent valuation for one part of the company for 1 billion dollars. You should investigate the company before you say things that are clearly not true imo.
Read the damn article!!!! This is a billion dollar company now!!!
Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of a woman’s lifetime, the odds are greater than 12% (or 1 out of every 8) that she will develop invasive breast cancer and have only about a 41% chance of surviving for 5 years if not detected until stage IIIB (odds are increased to approximately 90% if caught in stage I). Although most people don’t consider it, men aren’t removed from invasive breast cancer stats either; nearly 2,000 new cases were diagnosed in 2010 as well.
Given the high death rate for late-stage detection (odds slip all the way to a meager 15% chance of living 5 more years when detected in stage 4), there is a huge area of unmet need for new therapies to treat the disease. One company looking to make a dent in the number of breast cancer deaths is Montreal, Canada-based Sunshine Biopharma, Inc., a drug maker engaged in researching and developing drugs for a wide array of cancers with their initial focus on breast cancer.
Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery that are responsible for making cancer cells resistant to drugs. Multidrug resistance is a major component in the failure of many of today’s chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.
The life span of a biotech stock play runs in cycles with one area of common upward price movement being the commencement of clinical trials. Sunshine is nearing that milestone with McGill University’s The Jewish General Hospital already agreeing to host the Phase I clinical trials. A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.
https://drug-dev.com/sunshine-biopharma-looking-to-mimic-roches-billion-dollar-cancer-drug/
I may issue a rare purple alert... I have yet to decide.
which color can you see...I will personalize an alert for you. I am an equal opportunity stock pumper.
$SBFM- life changer- Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of a woman’s lifetime, the odds are greater than 12% (or 1 out of every 8) that she will develop invasive breast cancer and have only about a 41% chance of surviving for 5 years if not detected until stage IIIB (odds are increased to approximately 90% if caught in stage I). Although most people don’t consider it, men aren’t removed from invasive breast cancer stats either; nearly 2,000 new cases were diagnosed in 2010 as well.
Given the high death rate for late-stage detection (odds slip all the way to a meager 15% chance of living 5 more years when detected in stage 4), there is a huge area of unmet need for new therapies to treat the disease. One company looking to make a dent in the number of breast cancer deaths is Montreal, Canada-based Sunshine Biopharma, Inc., a drug maker engaged in researching and developing drugs for a wide array of cancers with their initial focus on breast cancer.
Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery that are responsible for making cancer cells resistant to drugs. Multidrug resistance is a major component in the failure of many of today’s chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.
The life span of a biotech stock play runs in cycles with one area of common upward price movement being the commencement of clinical trials. Sunshine is nearing that milestone with McGill University’s The Jewish General Hospital already agreeing to host the Phase I clinical trials. A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.
https://drug-dev.com/sunshine-biopharma-looking-to-mimic-roches-billion-dollar-cancer-drug/
RED ALERT- A doctor at the Jewish Hospital in Montreal confirmed that Adva-27a had arrived onsite and the trials have started.
See you at $2.
Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of a woman’s lifetime, the odds are greater than 12% (or 1 out of every 8) that she will develop invasive breast cancer and have only about a 41% chance of surviving for 5 years if not detected until stage IIIB (odds are increased to approximately 90% if caught in stage I). Although most people don’t consider it, men aren’t removed from invasive breast cancer stats either; nearly 2,000 new cases were diagnosed in 2010 as well.
Given the high death rate for late-stage detection (odds slip all the way to a meager 15% chance of living 5 more years when detected in stage 4), there is a huge area of unmet need for new therapies to treat the disease. One company looking to make a dent in the number of breast cancer deaths is Montreal, Canada-based Sunshine Biopharma, Inc., a drug maker engaged in researching and developing drugs for a wide array of cancers with their initial focus on breast cancer.
Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery that are responsible for making cancer cells resistant to drugs. Multidrug resistance is a major component in the failure of many of today’s chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.
The life span of a biotech stock play runs in cycles with one area of common upward price movement being the commencement of clinical trials. Sunshine is nearing that milestone with McGill University’s The Jewish General Hospital already agreeing to host the Phase I clinical trials. A thinly traded stock with a paltry market cap of under $30 million, biotech investors will be on the lookout for news of the human trials and any further cancer drug development news that could be the catalyst required to drive the share value to the next level.
https://drug-dev.com/sunshine-biopharma-looking-to-mimic-roches-billion-dollar-cancer-drug/
....could want shares....or attention.
I was buying from .09 to .30. No matter how much we paid I believe all of our shares have one thing in common- they are worth $2.
You should check out all the surrounding claims to see how active the area is for other miners. ;)
https://thediggings.com/usa/wyoming/map
Medrecycler opponents have already lost twice in court with the same arguments. The RI Supreme Court turned down their appeal. The lawyers for the opposition has already tried and failed.
I hope the mice bust out and escape because they are so healthy. If an orderly or nurse gets killed in the jail break then we will just call that "collateral damage". We (and the mice) are on a mission.
YES! GREEN ALERT!!!- YOU ARE GOING TO BE RICH!!
lol....Etrade customer service is now non-existent. I think I will just wait for the maiden resource report here, sell at $8 a share, and never worry about this again. ;)
I am not arguing with you...you are surely correct. I just don't understand it and need to figure out why it happens.
no...I move 4 times in a row and all 5 MMs moved in unison.
why would they all move with me? That doesn't make sense on any exchange.